<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124982</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-064</org_study_id>
    <nct_id>NCT00124982</nct_id>
  </id_info>
  <brief_title>Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy</brief_title>
  <official_title>A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to summarize the safety and tolerability of abatacept during 6
      months of combined treatment with one or more of the background non-biologic disease
      modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects
      with active RA. Secondary objectives assessed the clinical efficacy of combination treatment,
      including disease activity, physical function, and quality of life outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</measure>
    <time_frame>Days 1-169</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With AEs of Special Interest</measure>
    <time_frame>Days 1-169</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</measure>
    <time_frame>Days 1-169</time_frame>
    <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use 0.5 * BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</measure>
    <time_frame>Days 1-169</time_frame>
    <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</measure>
    <time_frame>Days 1-169</time_frame>
    <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</measure>
    <time_frame>Days 1-169</time_frame>
    <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Mean Change From Baseline in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Day 1 (Baseline) -Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</measure>
    <time_frame>Days 1-169</time_frame>
    <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With AEs of Special Interest</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Marked abnormality criteria=Hemoglobin: &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75*BL; Erythrocytes:&lt;0.75*BL; Platelets: &lt;0.67*LLN/&gt;1.5 * ULN, or if BL&lt;LLN, use 0.5*BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75*LLN/&gt;1.25*ULN, or if BL&lt;LLN, use &lt;0.8*BL/&gt;ULN, or if BL&gt;ULN,use &gt;1.2*BL/&lt;LLN; neutrophils+bands: &lt;1.0*10^3 c/uL; eosinophils: &gt;0.750*10^3 c/uL; basophils: &gt;400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750*10^3 c/uL/&gt;7.50*10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; aspartate aminotransferase (AST): &gt;3*ULN, or if BL&gt;ULN,use &gt;4*BL; alanine aminotransferase (ALT): &gt;3*ULN, or if BL&gt;ULN, use &gt;4*BL; G-Glutamyl transferase (GGT): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; bilirubin: &gt;2*ULN, or if BL&gt;ULN, use &gt;4*BL; blood urea nitrogen (BUN): &gt;2*BL; creatinine: &gt;1.5*BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>HGB normal range (NR)=11.6 - 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 - 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 - 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Hematocrit Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>The hematocrit value refers to the percentage of blood volume that is occupied by red blood cells. Hematocrit values for participants were expressed as percentages and were averaged to yield a group mean value (percentage) at a particular time point. The mean change from baseline in hematocrit value (expressed as a percent)= mean post-baseline value (expressed as a percent) - mean baseline value (expressed as a percent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Erythrocytes Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>Erythrocytes NR= 3.80 - 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Platelets (PLT) Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>Erythrocytes NR= 3.80 - 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in White Blood Cells Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>Leukocytes NR=4.1 - 12.3*10^3 c/uL, MA is &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN. Neutrophils+bands MA is &lt;1.0 * 10^3 c/uL. Eosinophils MA is &gt;0.750 * 10^3 c/uL. Basophils MA is &gt; 400 mm^3. Monocytes MA is &gt;2000 mm^3. Lymphocytes MA is &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>HGB normal range (NR)=11.6 - 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 - 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 - 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>Bilirubin NR=0.2-1.2 mg/dL, MA: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL. BUN NR=4.0-24.0 mg/dL, MA: &gt;2*BL. Creatinine NR=0.4-1.2 mg/dL, MA: &gt;1.5*BL. Ca NR=8.8-10.2 mg/dL, MA: &lt;0.8*LLN/&gt;1.2*ULN, or if BL&lt;LLN then use 0.75*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25*BL or &lt;LLN. P NR=2.8-4.0 mg/dL, MA: &lt;0.75*LLN/ &gt;1.25*ULN, or if BL&lt;LLN then use 0.67*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33*BL or &lt;LLN. Glu MA: &lt;65 mg/dL/ &gt;220 mg/dL. Uric acid MA: &gt;1.5*ULN, or if BL&gt;ULN then use &gt;2*BL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time</measure>
    <time_frame>BL, Day 365, Day 729</time_frame>
    <description>Na NR=132 - 147 mEq/L, MA is 95* LLN/ &gt;1.05* ULN, or if BL&lt;LLN then use 0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN. K NR=3.3 - 5.5 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN. Cl NR=94 - 111 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
    <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Mean Heart Rate (HR) Over Time</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Period: Mean Temperature (T) Over Time</measure>
    <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label</measure>
    <time_frame>BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169</time_frame>
    <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label</measure>
    <time_frame>BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with measurements available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Change From Baseline to Day 169 in High Sensitivity C-Reactive Protein (Hs-CRP)</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Change From Baseline to Day 169 in Rheumatoid Factor (RF)</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Change From Baseline to Day 169 in the Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants Achieving a Clinically Meaningful HAQ Response</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores</measure>
    <time_frame>BL</time_frame>
    <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Baseline Fatigue Visual Analog Scale (VAS)</measure>
    <time_frame>BL</time_frame>
    <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Mean Change From Baseline to Day 169 in Fatigue Visual Analog Scale (VAS)</measure>
    <time_frame>BL, Day 169</time_frame>
    <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time</measure>
    <time_frame>BL, Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0)values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL(Day 0)value for only that cohort of participants with measurements available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched mean change from BL = Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with data available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</measure>
    <time_frame>BL (Day 0)</time_frame>
    <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising,eating,walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched BL(Day 0)values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term</measure>
    <time_frame>Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising, eating, walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0(no difficulty), max overall score=3(unable to do). Post-BL values presented for each visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>HAQ-DI includes 20 questions assessing physical functions in 8 domains:dressing,arising,eating,walking,hygiene,reach,grip and common activities.Domain questions evaluated on 4-point scale: 0=without any difficulty,1=with some difficulty,2=with much difficulty,and 3=unable to do. HAQ-DI=sum of worst scores in each domain ÷ number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time</measure>
    <time_frame>BL, Days 365, 449, 533, 617, 729, 813</time_frame>
    <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</measure>
    <time_frame>BL (Day 0)</time_frame>
    <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health;(2) mental component summary=vitality,social functioning,role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score and 100=best score. Time-matched BL (Day 0) values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term</measure>
    <time_frame>Days 365 and 729</time_frame>
    <description>SF-36 measures health-related quality of life and has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Post-BL values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</measure>
    <time_frame>BL (Day 0), Days 365, 729</time_frame>
    <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LT; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</measure>
    <time_frame>Days 1-813</time_frame>
    <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1286</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Open-label Abatacept (ABA)-Previous User</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label ABA-Current User</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term ABA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.</description>
    <arm_group_label>Open-label Abatacept (ABA)-Previous User</arm_group_label>
    <arm_group_label>Open-label ABA-Current User</arm_group_label>
    <arm_group_label>Long-term ABA</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)</intervention_name>
    <description>During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).</description>
    <arm_group_label>Open-label Abatacept (ABA)-Previous User</arm_group_label>
    <arm_group_label>Open-label ABA-Current User</arm_group_label>
    <arm_group_label>Long-term ABA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Tumor Necrosing Factor (TNF) Therapy</intervention_name>
    <description>Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months</description>
    <arm_group_label>Open-label ABA-Current User</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed double-blind portion of the IM101064 study.

          -  Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis

          -  American College of Rheumatology (ACR) functional class I, II, III

          -  Subjects currently or previously received an anti-TNF therapy at an approved labeled
             dose for at least 3 months

        Exclusion Criteria:

          -  Subjects with active vasculitis of a major organ system (except subcutaneous
             rheumatoid nodules)

          -  History of cancer within the last 5 years (other than non-melanoma skin cell cancers
             cured by local resection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Petockey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manalapan</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hewlett</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Schenectady</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bismark</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Meadville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boisguillaume</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chambray Les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice Cedex 03</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guipuzcoa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leeds</city>
        <state>North Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov;68(11):1708-14. doi: 10.1136/ard.2008.099218. Epub 2008 Dec 15.</citation>
    <PMID>19074911</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2005</study_first_posted>
  <results_first_submitted>February 18, 2011</results_first_submitted>
  <results_first_submitted_qc>April 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2011</results_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 1286 participants enrolled in this study, 240 were not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Short Term (ST) Abatacept (ABA)-Previous User</title>
          <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
        </group>
        <group group_id="P2">
          <title>ST-Current User</title>
          <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
        </group>
        <group group_id="P3">
          <title>Long-term ABA</title>
          <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Short-term Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="449"/>
                <participants group_id="P2" count="597"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="483"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Chose Own Doctor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision-No Specific AE</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Had Lymphopenia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="530">A large number did not continue due to a rollover from study drug to commercially available drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Neurologist Recommendation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ST Abatacept (ABA)-Previous User</title>
          <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
        </group>
        <group group_id="B2">
          <title>ST ABA-Current User</title>
          <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="449"/>
            <count group_id="B2" value="597"/>
            <count group_id="B3" value="1046"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="12.5"/>
                    <measurement group_id="B2" value="53.2" spread="12.3"/>
                    <measurement group_id="B3" value="54.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="490"/>
                    <measurement group_id="B3" value="849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Tender Joints</title>
          <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count.</description>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.8" spread="5.9"/>
                    <measurement group_id="B2" value="17.8" spread="6.1"/>
                    <measurement group_id="B3" value="17.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Swollen Joints</title>
          <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count.</description>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="5.6"/>
                    <measurement group_id="B2" value="13.5" spread="5.4"/>
                    <measurement group_id="B3" value="13.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Function, Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.6"/>
                    <measurement group_id="B2" value="1.7" spread="0.6"/>
                    <measurement group_id="B3" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hs-C-Reactive Protein (hs-CRP) Serum Levels</title>
          <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="3.0"/>
                    <measurement group_id="B2" value="2.1" spread="3.0"/>
                    <measurement group_id="B3" value="2.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score (DAS) 28 (Using CRP Levels)</title>
          <description>The DAS28 (CRP) is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, serum CRP level, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="0.7"/>
                    <measurement group_id="B2" value="6.2" spread="0.7"/>
                    <measurement group_id="B3" value="6.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rheumatoid Factor (RF) Status</title>
          <description>Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
        <time_frame>Days 1-169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Days 1-169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Infections (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benign, malignant, and unspecified neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune disorders (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute infusional AEs (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-infusional AEs (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169</title>
        <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Clinically Meaningful Improvement (CMI) in Disease Activity Score (DAS 28), Low Disease Activity (LDAS), or Remission at Day 169</title>
          <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>All treated participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</title>
        <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use 0.5 * BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Days 1-169</time_frame>
        <population>Participants who received at least 1 infusion of abatacept during the short-term treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</title>
          <description>Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use 0.5 * BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>Participants who received at least 1 infusion of abatacept during the short-term treatment period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (n=429, n=581)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (n=428, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes (n=429, n=581)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (n=424, n=578)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT (n=424, n=578)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (n=429, n=581)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (n=429, n=581)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils+bands (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High basophils (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lymphocytes (n=429, n=580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
        <time_frame>Days 1-169</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; aspartate aminotransferase (AST): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; alanine aminotransferase (ALT): &gt;3* ULN, or if BL&gt;ULN then use &gt;4* BL; G-Glutamyl transferase (GGT): &gt;2* ULN, or if BL&gt;ULN then use &gt;3* BL; Bilirubin: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL; blood urea nitrogen (BUN): &gt;2* BL; creatinine: &gt;1.5* BL</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (n=426, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (n=426, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT (n=427, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High bilirubin (n=426, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (n=427, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
        <time_frame>Days 1-169</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Na (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Na (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K (n=425, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High K (n=425, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low chloride (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High chloride (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P (n=426, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High P (n=426, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Days 1-169</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu (n=427, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu (n=427, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High protein (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High uric acid (n=428, n=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein (n=298, n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine glucose (n=298, n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood (n=298, n=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine leukocyte esterase (n=297, n=491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC (n=68, n=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC (n=80, n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Mean Change From Baseline in Systolic and Diastolic Blood Pressure</title>
        <time_frame>Day 1 (Baseline) -Day 169</time_frame>
        <population>Although mean values for systolic and diastolic blood pressure were recorded, mean changes from baseline were not summarized for these data.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline in Systolic and Diastolic Blood Pressure</title>
          <population>Although mean values for systolic and diastolic blood pressure were recorded, mean changes from baseline were not summarized for these data.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</title>
        <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
        <time_frame>Days 1-169</time_frame>
        <population>Treated participants with available serum samples for assay</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated Participants</title>
            <description>Open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)</title>
          <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
          <population>Treated participants with available serum samples for assay</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-abatacept antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CTLA4 antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label</title>
        <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169</time_frame>
        <population>All treated participants. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Through 6 Month Open-Label</title>
          <description>The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants. n=number of evaluable participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="580"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 15 cohort (n=429,570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="0.73"/>
                    <measurement group_id="O2" value="6.17" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 visit (n=429,570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.46" spread="1.05"/>
                    <measurement group_id="O2" value="5.49" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 29 cohort (n=426,580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.72"/>
                    <measurement group_id="O2" value="6.17" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 visit (n=426,580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="1.20"/>
                    <measurement group_id="O2" value="5.09" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 57 cohort (n=425,563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.74"/>
                    <measurement group_id="O2" value="6.16" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 visit (n=425,563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="1.27"/>
                    <measurement group_id="O2" value="4.72" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 85 cohort (n=403,542)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="0.73"/>
                    <measurement group_id="O2" value="6.16" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 visit (n=403,542)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="1.37"/>
                    <measurement group_id="O2" value="4.57" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 113 cohort (n=393,516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" spread="0.73"/>
                    <measurement group_id="O2" value="6.15" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 visit (n=393,516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="1.36"/>
                    <measurement group_id="O2" value="4.39" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 141 cohort (n=372,493)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.74"/>
                    <measurement group_id="O2" value="6.16" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 visit (n=372,493)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="1.38"/>
                    <measurement group_id="O2" value="4.27" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 169 cohort(n=369,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.73"/>
                    <measurement group_id="O2" value="6.15" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 visit (n=369,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="1.43"/>
                    <measurement group_id="O2" value="4.14" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with measurements available at that post-BL visit.</description>
        <time_frame>BL (Day 0), Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169</time_frame>
        <population>All treated participants. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Through 6 Month Open-Label</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with measurements available at that post-BL visit.</description>
          <population>All treated participants. n=number of evaluable participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="580"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 15 visit (n=429,570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.04"/>
                    <measurement group_id="O2" value="-0.68" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 29 visit (n=426,580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.05"/>
                    <measurement group_id="O2" value="-1.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 57 visit (n=425,563)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="0.06"/>
                    <measurement group_id="O2" value="-1.44" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 85 visit (n=403,542)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.06"/>
                    <measurement group_id="O2" value="-1.60" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 113 visit(n=393,516)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.07"/>
                    <measurement group_id="O2" value="-1.76" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 141 visit(n=372,493)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="0.07"/>
                    <measurement group_id="O2" value="-1.90" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 169 visit(n=369,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="0.07"/>
                    <measurement group_id="O2" value="-2.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Change From Baseline to Day 169 in High Sensitivity C-Reactive Protein (Hs-CRP)</title>
        <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline to Day 169 in High Sensitivity C-Reactive Protein (Hs-CRP)</title>
          <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28.</description>
          <population>All treated participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.13"/>
                    <measurement group_id="O2" value="-0.68" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Change From Baseline to Day 169 in Rheumatoid Factor (RF)</title>
        <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline to Day 169 in Rheumatoid Factor (RF)</title>
          <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.</description>
          <population>All treated participants</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.2" spread="11.33"/>
                    <measurement group_id="O2" value="-22.8" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Change From Baseline to Day 169 in the Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do).</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline to Day 169 in the Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do).</description>
          <population>All treated participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.03"/>
                    <measurement group_id="O2" value="-0.41" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants Achieving a Clinically Meaningful HAQ Response</title>
        <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants Achieving a Clinically Meaningful HAQ Response</title>
          <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores</title>
        <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>BL</time_frame>
        <population>All treated participants. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Baseline Short Form 36 (SF-36) Quality of Life Physical Component Summary (PCS), Mental Component Summary (MCS), and SF-36 Individual Component Scores</title>
          <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>All treated participants. n=number of evaluable participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS (n=360, n=466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.81" spread="7.74"/>
                    <measurement group_id="O2" value="28.75" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS (n=360, n=466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.45" spread="12.98"/>
                    <measurement group_id="O2" value="42.43" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function Scale Component (n=367, n=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.72" spread="9.87"/>
                    <measurement group_id="O2" value="28.22" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical Scale Component (n=364, n=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.06" spread="7.95"/>
                    <measurement group_id="O2" value="31.38" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Scale Component (n=367, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.73" spread="7.17"/>
                    <measurement group_id="O2" value="31.13" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Scale Component (n=369, n=475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.70" spread="9.40"/>
                    <measurement group_id="O2" value="35.71" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Scale Component (n=369, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.95" spread="9.21"/>
                    <measurement group_id="O2" value="36.62" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Scale Component (n=370, n=475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.76" spread="11.86"/>
                    <measurement group_id="O2" value="34.13" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional Scale Component (n=365, n=471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.21" spread="13.99"/>
                    <measurement group_id="O2" value="36.98" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Scale Component (n=369, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.79" spread="12.79"/>
                    <measurement group_id="O2" value="41.92" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.Related AE/SAE=Certain,Probable,Possible,or Missing relationship to Drug</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune disorders (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-infusional AEs (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute infusional AEs (pre-specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</title>
        <description>ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Marked abnormality criteria=Hemoglobin: &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75*BL; Erythrocytes:&lt;0.75*BL; Platelets: &lt;0.67*LLN/&gt;1.5 * ULN, or if BL&lt;LLN, use 0.5*BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75*LLN/&gt;1.25*ULN, or if BL&lt;LLN, use &lt;0.8*BL/&gt;ULN, or if BL&gt;ULN,use &gt;1.2*BL/&lt;LLN; neutrophils+bands: &lt;1.0*10^3 c/uL; eosinophils: &gt;0.750*10^3 c/uL; basophils: &gt;400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750*10^3 c/uL/&gt;7.50*10^3 c/uL.</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>Participants who received at least 1 infusion of abatacept during the long-term treatment period. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) Criteria</title>
          <description>ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Marked abnormality criteria=Hemoglobin: &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75*BL; Erythrocytes:&lt;0.75*BL; Platelets: &lt;0.67*LLN/&gt;1.5 * ULN, or if BL&lt;LLN, use 0.5*BL/&lt;100,000 mm^3; Leukocytes: &lt;0.75*LLN/&gt;1.25*ULN, or if BL&lt;LLN, use &lt;0.8*BL/&gt;ULN, or if BL&gt;ULN,use &gt;1.2*BL/&lt;LLN; neutrophils+bands: &lt;1.0*10^3 c/uL; eosinophils: &gt;0.750*10^3 c/uL; basophils: &gt;400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750*10^3 c/uL/&gt;7.50*10^3 c/uL.</description>
          <population>Participants who received at least 1 infusion of abatacept during the long-term treatment period. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low hemoglobin (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low platelets (n=500)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High platelets (n=500)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils+bands (510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lymphocytes (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High basophils (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; aspartate aminotransferase (AST): &gt;3*ULN, or if BL&gt;ULN,use &gt;4*BL; alanine aminotransferase (ALT): &gt;3*ULN, or if BL&gt;ULN, use &gt;4*BL; G-Glutamyl transferase (GGT): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; bilirubin: &gt;2*ULN, or if BL&gt;ULN, use &gt;4*BL; blood urea nitrogen (BUN): &gt;2*BL; creatinine: &gt;1.5*BL</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria: Alkaline phosphatase (ALP): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; aspartate aminotransferase (AST): &gt;3*ULN, or if BL&gt;ULN,use &gt;4*BL; alanine aminotransferase (ALT): &gt;3*ULN, or if BL&gt;ULN, use &gt;4*BL; G-Glutamyl transferase (GGT): &gt;2*ULN, or if BL&gt;ULN, use &gt;3*BL; bilirubin: &gt;2*ULN, or if BL&gt;ULN, use &gt;4*BL; blood urea nitrogen (BUN): &gt;2*BL; creatinine: &gt;1.5*BL</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP (n=514)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High bilirubin (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria:Sodium (Na): &lt;0.95* LLN/ &gt;1.05* ULN,or if BL&lt;LLN then use 0.95* BL or &gt;ULN,or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN; potassium (K): &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; chloride: &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN; calcium (Ca): &lt;0.8* LLN/&gt;1.2* ULN, or if BL&lt;LLN then use 0.75* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25* BL or &lt;LLN; phosphorous (P): &lt;0.75* LLN/ &gt;1.25* ULN, or if BL&lt;LLN then use 0.67* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33* BL or &lt;LLN</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Na (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Na (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High K (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low chloride (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High chloride (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High P (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</title>
        <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA Criteria</title>
          <description>Marked abnormality criteria: serum glucose (Glu):&lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8* LLN/&gt;1.5* ULN, or if BL&lt;LLN then use 0.8* BL or &gt;ULN, or if BL&gt;ULN then use &gt;2.0* BL or &lt;LLN; total protein: &lt;0.9* LLN/&gt;1.1* ULN; albumin: &lt;0.9* LLN,or if BL&lt;LLN then use &lt;0.75 BL; uric acid: &gt;1.5* ULN, or if BL&gt;ULN then use &gt;2* BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]):Use ≥2 when BL value missing or value ≥4,or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>All treated participants. n=number of participants with evaluable laboratory results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low glu (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High glu (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High protein (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin (n=511)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High uric acid (n=513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein (n=462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine glucose (n=462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood (n=462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine leukocyte esterase (n=462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time</title>
        <description>HGB normal range (NR)=11.6 – 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 – 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 – 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over Time</title>
          <description>HGB normal range (NR)=11.6 – 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 – 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 – 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 HGB (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 total protein (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 albumin (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HGB (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 total protein (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 albumin (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Hematocrit Over Time</title>
        <description>The hematocrit value refers to the percentage of blood volume that is occupied by red blood cells. Hematocrit values for participants were expressed as percentages and were averaged to yield a group mean value (percentage) at a particular time point. The mean change from baseline in hematocrit value (expressed as a percent)= mean post-baseline value (expressed as a percent) - mean baseline value (expressed as a percent).</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Hematocrit Over Time</title>
          <description>The hematocrit value refers to the percentage of blood volume that is occupied by red blood cells. Hematocrit values for participants were expressed as percentages and were averaged to yield a group mean value (percentage) at a particular time point. The mean change from baseline in hematocrit value (expressed as a percent)= mean post-baseline value (expressed as a percent) - mean baseline value (expressed as a percent).</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 hematocrit (n=213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HGB (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Erythrocytes Over Time</title>
        <description>Erythrocytes NR= 3.80 – 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Erythrocytes Over Time</title>
          <description>Erythrocytes NR= 3.80 – 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>10^6 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 erythrocytes (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 erythrocytes (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Platelets (PLT) Over Time</title>
        <description>Erythrocytes NR= 3.80 - 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Platelets (PLT) Over Time</title>
          <description>Erythrocytes NR= 3.80 - 5.50 *10^6 c/uL, MA is &lt;0.75 * BL</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 PLT (n=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 PLT (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.7" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in White Blood Cells Over Time</title>
        <description>Leukocytes NR=4.1 - 12.3*10^3 c/uL, MA is &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN. Neutrophils+bands MA is &lt;1.0 * 10^3 c/uL. Eosinophils MA is &gt;0.750 * 10^3 c/uL. Basophils MA is &gt; 400 mm^3. Monocytes MA is &gt;2000 mm^3. Lymphocytes MA is &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in White Blood Cells Over Time</title>
          <description>Leukocytes NR=4.1 - 12.3*10^3 c/uL, MA is &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL/&gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL/&lt;LLN. Neutrophils+bands MA is &lt;1.0 * 10^3 c/uL. Eosinophils MA is &gt;0.750 * 10^3 c/uL. Basophils MA is &gt; 400 mm^3. Monocytes MA is &gt;2000 mm^3. Lymphocytes MA is &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 leukocytes (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 neutrophils (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 eosinophils (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 monocytes (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 basophils (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 lymphocytes (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 leukocytes (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 neutrophils (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 eosinophils (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 monocytes (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 basophils (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 lymphocytes (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time</title>
        <description>HGB normal range (NR)=11.6 - 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 - 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 - 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over Time</title>
          <description>HGB normal range (NR)=11.6 - 16.2 g/dL, marked abnormality (MA) is &gt;3 g/dL decrease from BL. Total protein NR=6.0 - 8.4 g/dL, MA is &lt;0.9* LLN/&gt;1.1* ULN; Albumin NR=3.5 - 5.3 g/dL, MA is &lt;0.9* LLN, or if BL&lt;LLN then use &lt;0.75 BL</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 ALP (n=218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 AST (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 ALT (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 GGT (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 ALP (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.44" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 AST (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 ALT (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 GGT (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time</title>
        <description>Bilirubin NR=0.2–1.2 mg/dL, MA: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL. BUN NR=4.0–24.0 mg/dL, MA: &gt;2*BL. Creatinine NR=0.4–1.2 mg/dL, MA: &gt;1.5*BL. Ca NR=8.8–10.2 mg/dL, MA: &lt;0.8*LLN/&gt;1.2*ULN, or if BL&lt;LLN then use 0.75*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25*BL or &lt;LLN. P NR=2.8–4.0 mg/dL, MA: &lt;0.75*LLN/ &gt;1.25*ULN, or if BL&lt;LLN then use 0.67*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33*BL or &lt;LLN. Glu MA: &lt;65 mg/dL/ &gt;220 mg/dL. Uric acid MA: &gt;1.5*ULN, or if BL&gt;ULN then use &gt;2*BL.</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over Time</title>
          <description>Bilirubin NR=0.2–1.2 mg/dL, MA: &gt;2* ULN, or if BL&gt;ULN then use &gt;4* BL. BUN NR=4.0–24.0 mg/dL, MA: &gt;2*BL. Creatinine NR=0.4–1.2 mg/dL, MA: &gt;1.5*BL. Ca NR=8.8–10.2 mg/dL, MA: &lt;0.8*LLN/&gt;1.2*ULN, or if BL&lt;LLN then use 0.75*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.25*BL or &lt;LLN. P NR=2.8–4.0 mg/dL, MA: &lt;0.75*LLN/ &gt;1.25*ULN, or if BL&lt;LLN then use 0.67*BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.33*BL or &lt;LLN. Glu MA: &lt;65 mg/dL/ &gt;220 mg/dL. Uric acid MA: &gt;1.5*ULN, or if BL&gt;ULN then use &gt;2*BL.</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 bilirubin (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 BUN (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 creatinine (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Ca (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 P (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Glu (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 uric acid (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 bilirubin (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 BUN (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 creatinine (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Ca (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 P (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Glu (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 uric acid (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time</title>
        <description>Na NR=132 – 147 mEq/L, MA is 95* LLN/ &gt;1.05* ULN, or if BL&lt;LLN then use 0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN. K NR=3.3 – 5.5 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN. Cl NR=94 – 111 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN</description>
        <time_frame>BL, Day 365, Day 729</time_frame>
        <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over Time</title>
          <description>Na NR=132 – 147 mEq/L, MA is 95* LLN/ &gt;1.05* ULN, or if BL&lt;LLN then use 0.95* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.05* BL or &lt;LLN. K NR=3.3 – 5.5 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN,or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN. Cl NR=94 – 111 mEq/L, MA is &lt;0.9* LLN/&gt;1.1* ULN, or if BL&lt;LLN then use 0.9* BL or &gt;ULN, or if BL&gt;ULN then use&gt;1.1* BL or &lt;LLN</description>
          <population>All treated participants in the OL. n=number of participants with evaluable laboratory results.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 Na (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 K (n=210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Cl (n=217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Na (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 K (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Cl (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time</title>
        <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable blood pressure measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over Time</title>
          <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
          <population>All treated participants. n=number of participants with evaluable blood pressure measurements.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 SBP pre-infusion (n=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.1" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 SBP post-infusion (n=478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.3" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 SBP pre-infusion (n=414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.4" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 SBP post-infusion (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.9" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 SBP pre-infusion (n=340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.9" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 SBP post-infusion (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.4" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 SBP pre-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 SBP post-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.9" spread="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 SBP pre-infusion (n=203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.2" spread="17.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 SBP post-infusion (n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 SBP pre-infusion (n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.1" spread="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 SBP post-infusion (n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.8" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 SBP pre-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 SBP post-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="18.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 SBP pre-infusion (n=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.2" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 SBP post-infusion (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 SBP pre-infusion (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.0" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 SBP post-infusion (n=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.1" spread="17.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 SBP post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.5" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 SBP post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.4" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 SBP pre-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.8" spread="18.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 SBP post-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="17.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 SBP pre-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.3" spread="19.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 SBP post-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.9" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 SBP pre-infusion (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="20.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 SBP post-infusion (n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.7" spread="17.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 SBP pre-infusion (n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.4" spread="16.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 SBP post-infusion (n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.2" spread="17.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 SBP pre-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 SBP post-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.6" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 SBP pre-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.6" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 SBP post-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 SBP pre-infusion (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.1" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 SBP post-infusion (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" spread="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 SBP pre-infusion (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.0" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 SBP post-infusion (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.8" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 SBP pre-infusion (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.4" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 SBP post-infusion (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.6" spread="17.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 SBP pre-infusion (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="16.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 SBP post-infusion (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.6" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 SBP pre-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.5" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 SBP post-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.9" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 SBP pre-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 SBP post-infusion (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 SBP pre-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.1" spread="19.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 SBP post-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.3" spread="18.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 SBP pre-infusion (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.4" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 SBP post-infusion (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.0" spread="14.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 SBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 SBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.1" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 SBP pre-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.6" spread="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 SBP post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.6" spread="14.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 SBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 SBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.4" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 SBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 SBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.2" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 SBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.8" spread="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 SBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.5" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 SBP pre-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" spread="16.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 SBP post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.4" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 SBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.8" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 SBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 SBP pre-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" spread="16.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 SBP post-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 SBP pre-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.1" spread="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 SBP post-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 SBP pre-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.5" spread="18.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 SBP post-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 SBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" spread="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 SBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.1" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 SBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.9" spread="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 SBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 SBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 SBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time</title>
        <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable blood pressure readings.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over Time</title>
          <description>Measurements were taken in a seated position before and after abatacept infusion.</description>
          <population>All treated participants. n=number of participants with evaluable blood pressure readings.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 DBP pre-infusion (n=481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 DBP post-infusion (n=477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 DBP pre-infusion (n=414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 DBP post-infusion (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 DBP pre-infusion (n=340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 DBP post-infusion (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 DBP pre-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 DBP post-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 DBP pre-infusion (n=203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 DBP post-infusion (n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 DBP pre-infusion (n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 DBP post-infusion (n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 DBP pre-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 DBP post-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 DBP pre-infusion (n=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 DBP post-infusion (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 DBP pre-infusion (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 DBP post-infusion (n=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 DBP post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 DBP post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 DBP pre-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 DBP post-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 DBP pre-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 DBP post-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 DBP pre-infusion (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 DBP post-infusion (n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 DBP pre-infusion (n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 DBP post-infusion (n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 DBP pre-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 DBP post-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 DBP pre-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 DBP post-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 DBP pre-infusion (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 DBP post-infusion (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 DBP pre-infusion (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 DBP post-infusion (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 DBP pre-infusion (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 DBP post-infusion (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 DBP pre-infusion (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 DBP post-infusion (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 DBP pre-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 DBP post-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 DBP pre-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 DBP post-infusion (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 DBP pre-infusion (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 DBP post-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 DBP pre-infusion (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 DBP post-infusion (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 DBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 DBP post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 DBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 DBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 DBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 DBP pre-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 DBP post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 DBP pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 DBP post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 DBP pre-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 DBP post-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 DBP pre-infusion (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 DBP post-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 DBP pre-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 DBP post-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 DBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 DBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 DBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 DBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 DBP pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 DBP post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Mean Heart Rate (HR) Over Time</title>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable heart rate readings.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Heart Rate (HR) Over Time</title>
          <population>All treated participants. n=number of participants with evaluable heart rate readings.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 HR pre-infusion (n=481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 HR post-infusion (n=481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 HR pre-infusion (n=414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 HR post-infusion (n=416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 HR pre-infusion (n=340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 HR post-infusion (n=338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 HR pre-infusion (n=252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 HR post-infusion (n=252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 HR pre-infusion (n=203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 HR post-infusion (n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 HR pre-infusion (n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 HR post-infusion (n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 HR pre-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 HR post-infusion (n=129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HR pre-infusion (n=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HR post-infusion (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 HR pre-infusion (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 HR post-infusion (n=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 HR post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 HR post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HR pre-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HR post-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 HR pre-infusion (n=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 HR post-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 HR pre-infusion (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 HR post-infusion (n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HR pre-infusion (n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HR post-infusion (n=66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 HR pre-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 HR post-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 HR pre-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 HR post-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HR pre-infusion (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HR post-infusion (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 HR pre-infusion (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 HR post-infusion (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 HR pre-infusion (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 HR post-infusion (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 HR pre-infusion (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 HR post-infusion (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HR pre-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HR post-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 HR pre-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 HR post-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 HR pre-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 HR post-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HR pre-infusion (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HR post-infusion (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 HR post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 HR post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 HR post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 HR post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 HR post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 HR pre-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 HR post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 HR pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 HR post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 HR pre-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 HR post-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 HR pre-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 HR post-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 HR pre-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 HR post-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 HR pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 HR post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 HR pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 HR post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 HR pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 HR post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Period: Mean Temperature (T) Over Time</title>
        <time_frame>From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept</time_frame>
        <population>All treated participants. n=number of participants with evaluable temperature readings.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Temperature (T) Over Time</title>
          <population>All treated participants. n=number of participants with evaluable temperature readings.</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 T pre-infusion (n=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 T post-infusion (n=478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 T pre-infusion (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 T post-infusion (n=413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 T pre-infusion (n=340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 T post-infusion (n=335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 T pre-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 T post-infusion (n=251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 T pre-infusion (n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 T post-infusion (n=202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 T pre-infusion (n=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 T post-infusion (n=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 T pre-infusion (n=129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 T post-infusion (n=128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 T pre-infusion (n=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 T post-infusion (n=119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 T pre-infusion (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393 T post-infusion (n=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 T post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 421 T post-infusion (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 T pre-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 T post-infusion (n=82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 T pre-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 477 T post-infusion (n=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 T pre-infusion (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 505 T post-infusion (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 T pre-infusion (n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 T post-infusion (n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 T pre-infusion (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 561 T post-infusion (n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 T pre-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 589 T post-infusion (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 T pre-infusion (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 T post-infusion (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 T pre-infusion (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 645 T post-infusion (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 T pre-infusion (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 673 T post-infusion (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 T pre-infusion (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 701 T post-infusion (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 T pre-infusion (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 T post-infusion (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 T pre-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 757 T post-infusion (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 T pre-infusion (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 785 T post-infusion (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 T pre-infusion (n=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 T post-infusion (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 T pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 841 T post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 T pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 869 T post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 T pre-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 T post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 T pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 925 T post-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 T pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 953 T post-infusion (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 T pre-infusion (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 T post-infusion (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 T pre-infusion (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1009 T post-infusion (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 T pre-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1037 T post-infusion (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 T pre-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1065 T post-infusion (n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 T pre-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 T post-infusion (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 T pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 T post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 T pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1149 T post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 T pre-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1177 T post-infusion (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores</title>
        <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline to Day 169 in SF-36 PCS, MCS, and SF-36 Individual Component Scores</title>
          <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>All treated participants. n=number of evaluable participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS (n=360, n=466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="0.44"/>
                    <measurement group_id="O2" value="6.08" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS (n=360, n=466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="0.59"/>
                    <measurement group_id="O2" value="5.43" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function Scale Component (n=367, n=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="0.52"/>
                    <measurement group_id="O2" value="4.66" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical Scale Component (n=364, n=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="0.59"/>
                    <measurement group_id="O2" value="6.82" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain Scale Component (n=367, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.20" spread="0.45"/>
                    <measurement group_id="O2" value="8.72" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health Scale Component (n=369, n=475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.38"/>
                    <measurement group_id="O2" value="3.83" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality Scale Component (n=369, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="0.51"/>
                    <measurement group_id="O2" value="6.37" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Scale Component (n=370, n=475)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" spread="0.58"/>
                    <measurement group_id="O2" value="7.18" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional Scale Component (n=365, n=471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="0.76"/>
                    <measurement group_id="O2" value="5.85" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Scale Component (n=369, n=472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="0.52"/>
                    <measurement group_id="O2" value="4.41" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Baseline Fatigue Visual Analog Scale (VAS)</title>
        <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
        <time_frame>BL</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Baseline Fatigue Visual Analog Scale (VAS)</title>
          <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
          <population>All treated participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33" spread="19.67"/>
                    <measurement group_id="O2" value="72.70" spread="20.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Mean Change From Baseline to Day 169 in Fatigue Visual Analog Scale (VAS)</title>
        <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
        <time_frame>BL, Day 169</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ST Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
          <group group_id="O2">
            <title>ST ABA-Current User</title>
            <description>In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Mean Change From Baseline to Day 169 in Fatigue Visual Analog Scale (VAS)</title>
          <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue.</description>
          <population>All treated participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="1.35"/>
                    <measurement group_id="O2" value="-20.2" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>BL, Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants. n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Clinically Meaningful Improvement in DAS 28, Low Disease Activity, or Remission Over Time</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>All treated participants. n=number of evaluable participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 CMI (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 LDAS (n=213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Remission (n=213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 CMI (n=119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 LDAS (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 Remission (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 CMI (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 LDAS (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 Remission (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 CMI (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 LDAS (n=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 Remission (79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 CMI (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 LDAS (n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Remission (n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 CMI (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 LDAS (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 Remission (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0)values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) DAS 28 and DAS 28 for Post-Baseline Visits Over the Long Term</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched baseline (Day 0)values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 cohort (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 visit (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 cohort (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 visit (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 cohort (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 visit (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 cohort (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 visit (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 cohort (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 visit (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 cohort (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.26" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 visit (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL(Day 0)value for only that cohort of participants with measurements available at that post-BL visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in DAS 28 Over The Long Term</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Time-matched mean change from BL= Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL(Day 0)value for only that cohort of participants with measurements available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 365 visit (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 449 visit (n=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 533 visit (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 617 visit (n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 729 visit (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 813 visit (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term</title>
        <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Tender Joints and Number of Tender Joints for Post-Baseline Visits Over the Long Term</title>
          <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 cohort (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.90" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 cohort (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.57" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 cohort (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.14" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 visit (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 cohort (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 visit (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 cohort (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 visit (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 cohort (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.42" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term</title>
        <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Number of Tender Joints Over the Long Term</title>
          <description>The mean number of tender joints was evaluated based on the number of tender joints in a standard 68 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 365 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 449 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 533 visit (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 617 visit (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 729 visit (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term</title>
        <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) Number of Swollen Joints And Post-Baseline Number of Swollen Joints Over the Long Term</title>
          <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 cohort (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.72" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 cohort (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 cohort (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.91" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 visit (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 cohort (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.98" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 visit (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 cohort (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 visit (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 cohort (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.40" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term</title>
        <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-Matched Change From Baseline (Day 0) in Number of Swollen Joints Over the Long Term</title>
          <description>The mean number of swollen joints was evaluated based on the number of swollen joints in a standard 66 joint count. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 365 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.16" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 449 visit (n=221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.87" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 533 visit (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.09" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 617 visit (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.01" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 729 visit (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.56" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term</title>
        <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) Hs-CRP Levels and Hs-CRP Levels for Post-Baseline Over the Long Term</title>
          <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 cohort (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 visit (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 cohort (n=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 visit (n=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 cohort (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 visit (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 cohort (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 visit (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 cohort (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 visit (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 cohort (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term</title>
        <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in Hs-CRP Level Over the Long Term</title>
          <description>hs-CRP is a acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). Levels of hs-CRP can be used to determine DAS28. Time-matched mean change from baseline = Post-baseline value - time-matched baseline value, where the time-matched baseline value represents the mean baseline (Day 0) value for only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 365 visit (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 449 visit (n=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 533 visit (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 617 visit (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 729 visit (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 813 visit (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term</title>
        <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) Visual Analog Scale (VAS) and VAS for Post-Baseline Visits Over the Long Term</title>
          <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit, and represent only that cohort of participants with measurements available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 cohort (n=220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.05" spread="16.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 visit (n=220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.61" spread="24.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 cohort (n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.20" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 visit (n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.74" spread="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 cohort (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.41" spread="15.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 visit (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.27" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 cohort (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.59" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 visit (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.16" spread="22.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 cohort (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.48" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 visit (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.90" spread="23.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 cohort (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.47" spread="16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 visit (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.61" spread="22.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term</title>
        <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched mean change from BL = Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with data available at that post-BL visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in VAS Over the Long Term</title>
          <description>The VAS for Fatigue (VAS-F) consists of a 100 mm line, with 0 (No Fatigue) on 1 end and 100 (Extreme Fatigue) on the other end, which a participant marks to indicate how much fatigue he or she feels. The marked point in mm is converted into a numeric value from 0 to 100, where 0=no fatigue and 100=maximum fatigue. Increasing numbers=increasing fatigue. Time-matched mean change from BL = Post-BL value - time-matched BL value, where the time-matched BL value represents the mean BL (Day 0) value for only that cohort of participants with data available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL (Day 0) to Day 365 visit (n=220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.4" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 449 visit (n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 533 visit (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.1" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 617 visit (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 729 visit (n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL (Day 0) to Day 813 visit (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.9" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
        <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising,eating,walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched BL(Day 0)values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
        <time_frame>BL (Day 0)</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
          <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising,eating,walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched BL(Day 0)values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 HAQ-DI (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ dressing and grooming (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ arising (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ eating (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ walking (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ hygiene (n=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ reaching (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ gripping (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ activities (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ-DI (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ dressing and grooming (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ arising (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ eating (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ walking (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ hygiene (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ reaching (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ gripping (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ activities (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ-DI (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ dressing and grooming (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ arising (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ eating (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ walking (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ hygiene (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ reaching (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ gripping (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ activities (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ-DI (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ dressing and grooming (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ arising (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ eating (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ walking (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ hygiene (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ reaching (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ gripping (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ activities (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ-DI (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ dressing and grooming (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ arising (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ eating (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ walking (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ hygiene (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ reaching (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ gripping (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ activities (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ-DI (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ dressing and grooming (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ arising (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ eating (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ walking (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ hygiene (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ reaching (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ gripping (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ activities (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term</title>
        <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising, eating, walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0(no difficulty), max overall score=3(unable to do). Post-BL values presented for each visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
        <time_frame>Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean HAQ-DI and HAQ-DI Component Scores For Participant Cohorts at Post-baseline Visits Over the Long Term</title>
          <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains:dressing, arising, eating, walking, hygiene, reach, grip and common activities. Domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. HAQ-DI= sum of worst scores in each domain divided by number of domains answered. HAQ-DI minimum=0(no difficulty), max overall score=3(unable to do). Post-BL values presented for each visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 HAQ-DI (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ dressing and grooming (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ arising (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ eating (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ walking (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ hygiene (n=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ reaching (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ gripping (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ activities (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ-DI (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ dressing and grooming (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ arising (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ eating (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ walking (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ hygiene (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ reaching (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ gripping (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ activities (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ-DI (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ dressing and grooming (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ arising (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ eating (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ walking (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ hygiene (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ reaching (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ gripping (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ activities (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ-DI (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ dressing and grooming (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ arising (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ eating (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ walking (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ hygiene (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ reaching (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ gripping (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ activities (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ-DI (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ dressing and grooming (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ arising (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ eating (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ walking (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ hygiene (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ reaching (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ gripping (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ activities (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ-DI (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ dressing and grooming (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ arising (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ eating (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ walking (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ hygiene (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ reaching (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ gripping (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ activities (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
        <description>HAQ-DI includes 20 questions assessing physical functions in 8 domains:dressing,arising,eating,walking,hygiene,reach,grip and common activities.Domain questions evaluated on 4-point scale: 0=without any difficulty,1=with some difficulty,2=with much difficulty,and 3=unable to do. HAQ-DI=sum of worst scores in each domain ÷ number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-BL visit.</description>
        <time_frame>BL (Day 0), Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in HAQ-DI and HAQ-DI Components For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
          <description>HAQ-DI includes 20 questions assessing physical functions in 8 domains:dressing,arising,eating,walking,hygiene,reach,grip and common activities.Domain questions evaluated on 4-point scale: 0=without any difficulty,1=with some difficulty,2=with much difficulty,and 3=unable to do. HAQ-DI=sum of worst scores in each domain ÷ number of domains answered. HAQ-DI minimum=0 (no difficulty), max overall score=3(unable to do). Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 HAQ-DI (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ dressing and grooming (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ arising (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ eating (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ walking (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ hygiene (n=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ reaching (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ gripping (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HAQ activities (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ-DI (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ dressing and grooming (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ arising (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ eating (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ walking (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ hygiene (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ reaching (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ gripping (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 HAQ activities (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ-DI (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ dressing and grooming (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ arising (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ eating (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ walking (n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ hygiene (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ reaching (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ gripping (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 HAQ activities (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ-DI (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ dressing and grooming (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ arising (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ eating (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ walking (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ hygiene (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ reaching (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ gripping (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 HAQ activities (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ-DI (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ dressing and grooming (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ arising (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ eating (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ walking (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ hygiene (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ reaching (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ gripping (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HAQ activities (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ-DI (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ dressing and grooming (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ arising (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ eating (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ walking (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ hygiene (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ reaching (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ gripping (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 HAQ activities (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time</title>
        <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>BL, Days 365, 449, 533, 617, 729, 813</time_frame>
        <population>All treated participants. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants Achieving Clinically Meaningful HAQ Response Over Time</title>
          <description>HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. HAQ-DI= sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from a minimum of 0 (no difficulty) to a maximum overall score of 3(unable to do). Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>All treated participants. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
        <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health;(2) mental component summary=vitality,social functioning,role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score and 100=best score. Time-matched BL (Day 0) values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit</description>
        <time_frame>BL (Day 0)</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Baseline (Day 0) SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
          <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health;(2) mental component summary=vitality,social functioning,role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score and 100=best score. Time-matched BL (Day 0) values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 PCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.96" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 MCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.09" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Physical Function Scale Component (n=306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.04" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Physical Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.17" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Bodily Pain Scale Component (n=305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.07" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 General Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.04" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Vitality Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.96" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Social Functioning Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.31" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Emotional Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.80" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Mental Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.89" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 PCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.76" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 MCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.06" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Physical Function Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.66" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Physical Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.87" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Bodily Pain Scale Component (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.35" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 General Health Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.23" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Vitality Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.77" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Social Functioning Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.59" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Emotional Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.30" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Mental Health Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.67" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term</title>
        <description>SF-36 measures health-related quality of life and has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Post-BL values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
        <time_frame>Days 365 and 729</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Post-baseline Visits Over the Long Term</title>
          <description>SF-36 measures health-related quality of life and has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Post-BL values presented for each post-BL visit represent only that cohort of participants with measurements available at that post-BL visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean post-baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 PCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 MCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.15" spread="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Physical Function Scale Component (n=306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Physical Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.85" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Bodily Pain Scale Component (n=305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.78" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 General Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.58" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Vitality Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.82" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Social Functioning Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.24" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Emotional Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.63" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Mental Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 PCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 MCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.06" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Physical Function Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.91" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Physical Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.61" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Bodily Pain Scale Component (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.89" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 General Health Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.99" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Vitality Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.94" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Social Functioning Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.28" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Emotional Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.37" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Mental Health Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.02" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
        <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-baseline visit.</description>
        <time_frame>BL (Day 0), Days 365, 729</time_frame>
        <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Abatacept (ABA)-Previous User</title>
            <description>In participants who had previously used Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing &lt; 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Mean Time-matched Change From Baseline (Day 0) in SF-36 PCS, MCS, and SF-36 Individual Component Scores For Participant Cohorts at Each Corresponding Post-baseline Visit Over the Long Term</title>
          <description>SF-36 has 36 questions with 8 subscale scores and 2 summary scores (1)physical component summary=physical functioning,role-physical,bodily pain,and general health; (2)mental component summary=vitality,social functioning,role-emotional,and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0=worst score and 100=best score. Time-matched mean change from BL= Post-BL value - time-matched BL value. Time-matched BL value=mean BL (Day 0)value for only that cohort with data available at that post-baseline visit.</description>
          <population>All treated participants analyzed in the LT. N=the total number of participants analyzed, n=the number of participants at that time point with available measurements. Mean time-matched baseline values reflect changing n-values over time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 PCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 MCS (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Physical Function Scale Component (n=306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Physical Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Bodily Pain Scale Component (n=305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.70" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 General Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Vitality Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Social Functioning Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Role-Emotional Scale Component (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Mental Health Scale Component (n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 PCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 MCS (n=83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Physical Function Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Physical Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Bodily Pain Scale Component (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.54" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 General Health Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Vitality Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Social Functioning Scale Component (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Role-Emotional Scale Component (n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Mental Health Scale Component (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LT; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</title>
        <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
        <time_frame>Days 1-813</time_frame>
        <population>Treated participants with available serum samples for assay</population>
        <group_list>
          <group group_id="O1">
            <title>Long-term ABA</title>
            <description>Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.</description>
          </group>
        </group_list>
        <measure>
          <title>LT; Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by ELISA</title>
          <description>Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.</description>
          <population>Treated participants with available serum samples for assay</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-abatacept antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CTLA4 antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Abatacept (LT)</title>
        </group>
        <group group_id="E2">
          <title>Abatacept (ST)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CARDIOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RETCHING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PROCTITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GALLBLADDER ENLARGEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>MEDICAL OBSERVATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BLOOD SODIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>METATARSALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>TENDON DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CERVICAL ROOT PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>POLYMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PULMONARY BULLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>PULMONARY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1046"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="530"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1046"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

